AstraZeneca buys heart drug firm Omthera for up to $443 mln
LONDON May 28 (Reuters) - AstraZeneca has agreed to buy Omthera Pharmaceuticals for up to $443 million to build up its cardiovascular drug business, which Britain's second biggest drugmaker has previously identified as a priority area.
AstraZeneca said on Tuesday it had entered into a definitive agreement to buy Omthera for $12.70 per share, or approximately $323 million, a premium of 88 percent on Omthera's closing price on Friday.
In addition, Omthera shareholders will get contingent value rights (CVRs) of up to approximately $4.70 per share, or $120 million in total, depending on the success of Omthera's experimental drug Epanova for treating patients with very high triglycerides, a type of blood fat that is bad for the heart.
- U.S. nurse defies Maine's Ebola quarantine, takes bike ride |
- Clashes erupt as Israeli police kill Palestinian suspected of shooting Jewish far-rightist
- SoftBank's humanoid robot lands job as Nescafe salesman
- Ukraine gas supplies in doubt as Russia seeks EU payment deal
- Dollar surges as Fed ends QE on hawkish note